A Standardized Protocol for Mouse Longevity Studies in Preclinical Drug Development.

Area of Science:

• Gerontology
• Pharmacology
• Toxicology

Background:

• Aging is a significant factor in chronic disease, yet preclinical drug development rarely assesses drug impact on lifespan.
• Current drug development lacks standardized mouse lifespan study protocols, hindering the evaluation of long-term therapeutic effects.
• High costs, limited commercial incentives, and regulatory concerns impede the incorporation of longevity studies in drug discovery.

Purpose of the Study:

• To present a comprehensive and scalable protocol for mouse longevity studies in early drug development.
• To establish a standardized framework for integrating lifespan assessments into routine preclinical evaluations.
• To facilitate the discovery of therapeutics that impact aging and chronic disease management.

Main Methods:

• A basic longevity study design using approximately 250 genetically heterogeneous UM-HET3 mice per group (176 males, 72 females).
• Survival curves as the primary endpoint for assessing longevity.
• Proposes enhanced study design options contingent on available budget.

Main Results:

• The proposed protocol offers a standardized foundation for longevity assessments in drug development.
• The framework can uncover long-term risks or benefits missed by traditional toxicology studies.
• Implementation supports the development of safer therapeutics and identifies potential geroprotectors.

Conclusions:

• Standardized mouse longevity studies are essential for comprehensive preclinical drug evaluation.
• This protocol provides a cost-effective and scalable approach to assess drug effects on lifespan.
• Integrating longevity studies can advance the development of chronic disease treatments and anti-aging interventions.